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Abstract
Purpose: The Veterans Health Administration (VHA) Clinical Pharmacogenetics Subcommittee 
is charged with making recommendations about whether specific pharmacogenetic tests should be 
used in healthcare at VHA facilities. We describe a process to inform VHA pharmacogenetic 
testing policy.
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Methods: After developing consensus definitions of clinical validity and utility, the 
Subcommittee identified salient drug-gene pairs with potential clinical application in VHA. 
Members met monthly to discuss each drug-gene pair, the evidence of clinical utility for the 
associated pharmacogenetic test, and any VHA-specific testing considerations. The Subcommittee 
classified each test as strongly recommended, recommended, or not routinely recommended 
before drug initiation.
Results: Of 30 drug-gene pair tests reviewed, the Subcommittee classified 4 (13%) as strongly 
recommended, including HLA-B*15:02 for carbamazepine-associated Stevens-Johnston syndrome 
and G6PD for rasburicase-associated hemolytic anemia; 12 (40%) as recommended, including 
CYP2D6 for codeine toxicity; and 14 (47%) as not routinely recommened, such as CYP2C19 for 
clopidogrel dosing.
Conclusion: Only half of drug-gene pairs with high clinical validity received Subcommittee 
support for policy promoting their widespread use across VHA. The Subcommittee generally 
found insufficient evidence of clinical utility or available, effective alternative strategies for the 
remainders. Continual evidence review and rigorous outcomes research will help promote the 
translation of pharmacogenetic discovery to healthcare.
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INTRODUCTION
Defined as the study of how genotype impacts the efficacy and toxicity an individual 
experiences from medications, pharmacogenetics has been touted as an early clinical 
application of genomics that might have a transformative impact on the routine practice of 
medicine.1–3 The U.S. Food and Drug Administration (FDA) labels for almost 200 
medications include pharmacogenetics considerations,4 and a recent analysis found that 91% 
of approximately 10,000 patients in one large health care system had at least one 
“actionable” pharmacogenetic variant associated with one of five commonly used 
medications.5 Catalyzed in part by advances in genome sequencing technology and the 
increasing availability of large patient data sets, pharmacogenetic discovery has seen 
exponential growth in recent years.6,7 Many health care systems are now integrating large 
pharmacogenetics programs into their patient care activities, through research studies, 
clinical implementation projects, or a combination of both.8–14
The Veterans Health Administration (VHA) of the U.S. Department of Veterans Affairs is 
the largest integrated health care system in the United States, providing primary and 
specialty care for more than 9 million Veterans each year, spanning every state and U.S. 
territory. Policymaking and oversight of laboratory testing in the VHA occurs at several 
levels, from the Office of the National Director of the Pathology and Laboratory Medicine 
Service (P&LMS) to the more than 145 P&LMS Chiefs or Directors and Administrative 
Laboratory Chiefs at local and regional VHA facilities nationwide.15 The P&LMS Chief or 
Director at each VHA facility is the steward of that facility’s P&LMS budget and is 
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responsible for overseeing all in-house and ancillary laboratory testing ordered at that 
facility, including the evaluation of a given test’s appropriateness.
However, the VHA currently lacks a standardized national approach to the clinical use of 
pharmacogenetic testing. Despite a substantial body of literature supporting the clinical 
validity of several pharmacogenetic associations, there has been a paucity of evidence of 
clinical utility and cost-effectiveness with respect to many of the pharmacogenetic tests in 
variable use across VHA locations. Clinicians might overutilize certain tests based on 
vendors’ recommendations, political pressure, or practices from academic affiliations. On 
the other hand, they might underutilize tests due to lack of knowledge or systems-level 
barriers to test ordering. With its common electronic health record (EHR) that includes both 
laboratory test results and pharmacy records, VHA is uniquely positioned to use and benefit 
from pharmacogenetic testing in patient care. However, the variation in clinical 
pharmacogenetics practice across the health system contributes to a lack of consensus on 
whether the costs of pharmacogenetic testing should be borne by the P&LMS, Pharmacy 
Service, or both at VHA locations.
In 2013, the National Director of P&LMS created a Molecular Diagnostics Working Group 
to develop a standardized VHA approach to molecular genetics diagnostic testing. The aims 
of the working group were to provide recommendations on how to effectively utilize 
molecular genetic tests, promote the quality and availability of testing across VHA, 
encourage internal referral testing, and inform P&LMS policy for molecular genetic testing 
and laboratory developed tests. The VHA Molecular Diagnostics Working Group consists of 
several subcommittees, including Oncology, Germline/Inherited Genetics, 
Hematopathology, Microbial Genetics, and Clinical Pharmacogenetics. To illustrate how one 
large integrated health system is approaching policymaking aroung pharmacogenetic testing, 
here we describe the first two years of the Clinical Pharmacogenetics Subcommittee’s 
activities in reviewing the scientific evidence for and making policy recommendations about 
its routine use.
MATERIALS AND METHODS
Clinical Pharmacogenetics Subcommittee charge and consensus definitions
The Clinical Pharmacogenetics Subcommittee (hereafter, the “Subcommittee”), is comprised 
of VHA and non-VHA experts in the fields of pharmacology, laboratory medicine, medical 
genetics, and health services research. In 2014, the Molecular Diagnostics Working Group 
recognized the lack of consistency in how VHA laboratories across the U.S. were using 
pharmacogenetic testing in clinical care. For example, there was variable use of CYP2D6 
and CYP2C19 genotyping to guide pharmacotherapy for major depressive disorder. To 
address this lack of policy and uniform practice, the Molecular Diagnostics Working Group 
charged the Subcommittee with making recommendations for standardizing 
pharmacogenetic testing across VHA. These recommendations would then be forwarded to 
the VHA Office of Specialty Care Services to inform VHA policymaking around 
pharmacogenetic testing.
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When the Subcommittee first convened, it recognized the need for a process to evaluate 
specific pharmacogenetic tests. Members understood that the strength of the scientific 
evidence supporting individual drug-gene and drug-variant associations is variable,16,17 and 
they were familiar with several existing resources and professional organizations 
endeavoring to standardize the field. These included PharmGKB (https://
www.pharmgkb.org), sponsored by the U.S. National Institutes of Health, which curates 
knowledge about the impact of genetic variation on drug response for clinicians and 
researchers.18 Some Subcommittee members were also members of the Clinical 
Pharmacogenetics Implementation Consortium (CPIC, https://cpicpgx.org), which performs 
systematic evidence grading of pharmacogenetic tests and, going one step further in clinical 
translation than PharmGKB, issues prescribing and dosing recommendations for specific 
medications if genotype information is available.17,19
The Subcommittee recognized that its role was not to recreate the work of these 
organizations but, rather, to incorporate and adapt it to inform policy recommendations for 
whether and how to use pharmacogenetic testing in VHA patient care. This recognition led 
to a discussion of the distinction between clinical validity and clinical utility, informed 
largely by the hierarchical ACCE model that evaluates a genetic test by its Analytic validity, 
Clinical validity, Clinical utility, and Ethical, legal, and social implications.20 To guide its 
activities, the Subcommittee used a consensus approach to generate the following working 
definitions of these key concepts specific to pharmacogenetic testing:
Pharmacogenetics is the study of inherited genetic differences in drug metabolic 
pathways (absorption, distribution, metabolism, or excretion) which can affect 
individual responses to drugs in terms of therapeutic and/or adverse effects. The 
analytic validity of a pharmacogenetic test refers to the ability of the test to 
accurately identify the genotype of interest. The clinical validity of a 
pharmacogenetic test result refers to the likelihood that the test result (genotype) 
provides information about therapeutic efficacy or toxicity. The clinical utility of a 
pharmacogenetic test result refers to the likelihood that pharmacogenetic 
information will lead to a change in clinical management that improves health 
outcomes. The clinical utility of pharmacogenetics also describes its ability to 
identify the right drug or drug combinations at the correct dosages, thereby 
maximizing benefits to the patient while minimizing toxicity.
Using these definitions, the Subcommittee recognized that the work of PharmGKB and 
CPIC most closely aligned with the concepts of analytic and clinical validity and that CPIC 
dosing guidelines were designed to help clinicians understand how available 
pharmacogenetic test results should be used to optimize drug therapy, rather than whether 
tests should be ordered. The Subcommittee thus specified its aim to evaluate the evidence 
supporting the clinical utility of specific pharmacogenetic tests, using the above definitions.
Choice of drug-gene pairs to review
To generate a list of pharmacogenetic tests with potential clinical utility, the Subcommittee 
identified drug-gene pairs from PharmGKB and CPIC with clinically valid genotype-
phenotype associations, drawing predominantly from CPIC Level A, which indicates a 
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strong recommendation that specific pharmacogenetic results, if known, should be used to 
inform the prescribing of the drug in question.17 The Subcommittee excluded drug-gene 
pairs addressed by other Molecular Diagnostics Working Group subcommittees, including 
FDA-approved companion diagnostics for oncology targeted thereapy such as afatinib-
EGFR, crizotinib-ALK, erlotinib-EGFR, and trametinib-BRAF V600. Drug-gene pairs 
relevant exclusively to pediatric populations were not considered. By March 2015, the 
Subcommittee had chosen 30 drug-gene pairs for review (Table 1).
Evidence review and synopsis
Subcommittee members were each assigned drug-gene pairs to review. For each drug-gene 
pair, the reviewer was asked to complete a review template summarizing the indications for 
drug use, mechanism of action, pharmacokinetics, and pharmacogenetics of the medication 
(Supplemental Materials and Methods). Reviewers consulted the databases of clinical and 
research pharmacogenetic groups from the government and private sector, including the 
FDA, the PharmacoGenomics Mutation Database (PGMD), the Human Cytochrome P450 
Allele Nomenclature Database (now a part of the PharmVar Consortium21), PharmaADME,
22
 the International Serious Adverse Events Consortium (iSAEC),23 and the UCSF 
Pharmacogenetics of Membrane Transporters (PMT) Database.24 Each reviewer was also 
asked to include PharmGKB and CPIC levels of evidence, in addition to any 
pharmacogenetic considerations on the drug’s FDA label. As applicable, each reviewer 
listed specific gene variants included in their review.
Consensus process for pharmacogenetic testing recommendations
On monthly teleconferences, members presented their review summaries to the 
Subcommittee. All members had the opportunity to ask questions and discuss the clinical 
relevance and utility of testing for that drug-gene association in clinical care across the 
VHA. Based on the review summary and the ensuing discussion, the presenting 
Subcommittee member was asked to provide a recommendation for whether routine 
pharmacogenetic testing for that drug-gene association should be 1) Strongly recommended 
for the use of that drug in VHA, 2) Recommended for the use of that drug in VHA, or 3) Not 
routinely recommended for the use of that drug in VHA. Of note, the Subcommittee 
intended these recommendations for general application to the routine initiation of the 
medications in question, and members had the option to add annotations for specific clinical 
contexts and patient characteristics for which the recommendations might differ from the 
general recommendation. The Subcommittee did not explicitly consider genotype frequency 
or the costs of testing in its deliberation. If a quorum was present, the Subcommittee voted 
by majority rule on whether to approve the recommendation. It is important to note that the 
Subcommittee’s evidence review and ensuing recommendations did not establish VHA 
policy but, rather, would be forwarded as policy guidance to the VHA Office of Specialty 
Care Services.
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RESULTS
Subcommittee recommendations
The Subcommittee reviewed 30 drug-gene pairs between February 2016 and April 2017 
(Table 1 and Supplemental Materials and Methods). By design, all 30 had CPIC 
recommendations of Level A strength. All but two had PharmGKB level of evidence 1A at 
the time of review (Table 1), indicating variant-drug combinations with strong evidence of 
genotype-phenotype association (clinical validity) that have a CPIC or other medical 
society-endorsed pharmacogenetic guideline or are implemented at a Pharmacogenomics 
Research Network site or in another major health system.18
The Subcommittee determined that 4 (13%) of the 30 pharmacogenetic tests should be 
strongly recommended before prescribing the associated drug, 12 (40%) should be 
recommended, and 14 (47%) should not be routinely recommended for clinical care across 
the VHA (Table 1 and Supplemental Materials and Methods). Table 1 summarizes the 
Subcommittee’s deliberations about each drug-gene pair. Although this rubric was not 
defined a priori, the Subcommittee’s recommendations point to some general observations. 
Testing tended to be strongly recommended if the phenotype was a severe adverse drug 
effect (ADE) that could be avoided with alternative therapy. Recommended tests could 
inform either the risk of ADE or drug efficacy; tests related to an ADE tended to be 
recommended and not strongly recommended if the associated medication was already in 
very widespread use across VHA (e.g. allopurinol and phenytoin), potentially making 
system-wide implementation unwieldy. Tests that were not routinely recommended tended 
to inform drug efficacy but lacked studies demonstrating improved patient outcomes. The 
following examples illustrate these three categories and the Subcommittee’s associated 
discussions.
Strongly recommended: HLA-B*57:01 genotyping for abacavir use
Abacavir is a nucleoside analog reverse transcriptase inhibitor used in the treatment of 
human immunodeficiency virus (HIV) infection. The medication is generally well tolerated, 
but 5–8% of patients experience a hypersensitivity reaction during the first 6 weeks of 
treatment, characterized by rash, fever, fatigue, cough, gastrointestinal symptoms, 
hypotension, and possibly death. The association between human leukocyte antigen (HLA)-
B*57:01 and abacavir hypersensitivity has been replicated in several studies, and a large 
prospective randomized controlled trial has demonstrated the complete avoidance of 
hypersensitivity reactions among patients prescreened for HLA-B*57:01 prior to therapy. 
Since 2008, the FDA label for abacavir has recommended HLA-B*57:01 testing prior to 
initiation and has issued a boxed warning that abacavir not be prescribed to any patient 
testing positive for HLA-B*57:01.25
The Subcommittee endorsed strongly recommending HLA-B*57:01 genotyping prior to 
abacavir use in the VHA. Factors supporting this recommendation included the availability 
of strong evidence for the clinical validity of the association between HLA-B*57:01 
genotype and abacavir hypersensitivity and the high negative predictive value of a negative 
HLA-B*57:01 genetic result. Perhaps more importantly, the Subcommittee valued the 
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availability of randomized trial data demonstrating improved patient outcomes (i.e. 
avoidance of hypersensitivity reactions after a prescreening intervention) and the ability of 
HLA-B*57:01 results to inform the choice between therapy with abacavir and other 
available antiretroviral medications.
Recommended: CYP2D6 genotyping for codeine use
Codeine is an opioid agonist analgesic with relative selectivity for the μ-opioid receptor. It is 
metabolized to morphine in the liver by cytochrome P450 2D6 (CYP2D6). As a result, high 
codeine intake can cause morphine intoxication, characterized by sedation, confusion, 
respiratory depression, and even death. The CYP2D6 gene is highly polymorphic, but 
genotypes can be broadly classified into poor, intermediate, normal (formerly referred to as 
extensive), and ultrarapid metabolizers. In its 2012 and 2014 guidelines, CPIC 
recommended that codeine not be prescribed for patients with ultrarapid metabolizer 
genotypes, given the risk of toxicity. At the other extreme, CPIC also recommended that 
codeine be avoided for poor metabolizers, given the possible analgesic inefficacy of codeine 
in those individuals.26
The Subcommittee recommended that prescribers consider CYP2D6 genotyping prior to 
codeine use in the VHA. Factors supporting this recommendation again included the 
actionability of the genetic test result, guiding prescribers to different codeine dosing or 
alternate analgesic agents. Members acknowledged the pressing concerns of the current 
opioid use disorder epidemic across the United States broadly and the VHA specifically and 
valued the potential of this test to guide more thoughtful approaches to pain management. 
The Subcommittee did not vote to strongly recommend CYP2D6 genotyping prior to 
codeine use, however. They reasoned that codeine is rarely prescribed as a single agent or 
for long-term use in the VHA patient population, more commonly prescribed in cough 
syrups (e.g. guaifenesin-codeine) or in combination with acetaminophen (“Tylenol® No.3”).
Not routinely recommended: CYP2C19 genotyping for clopidogrel use
Clopidogrel is a widely used prodrug that inhibits platelet aggregation, used in the treatment 
of cardiovascular diseases including acute coronary syndrome, stroke, and peripheral arterial 
disease. It is metabolized to its active metabolite predominantly by CYP2C19, whose 
haplotypes can be categorized as poor, intermediate, normal, rapid, and ultrarapid 
metabolizers. The 2013 CPIC guidelines recommend that patients who are intermediate or 
poor metabolizers based on CYP2C19 genotype be prescribed alternate antiplatelet therapy, 
such as prasugrel or ticagrelor, out of concern for lack of efficacy and the possibility of 
increased incidence of cardiovascular events.27
The Subcommittee did not routinely recommend CYP2C19 genotyping for the initiation of 
clopidogrel in VHA. Members considered a few factors in arriving at this recommendation. 
First, the Subcommittee acknowledged the availability of an alternate test, such as platelet 
aggregometry, that could produce similar clinical information. Second, clopidogrel is widely 
used across VHA, and a recommendation for routine CYPC19 testing could place 
tremendous burden on the healthcare system, given the dearth of VHA laboratories able to 
perform CYPC19 genotyping. Third, no randomized trial had demonstrated improved 
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clinical outcomes from CYP2C19 testing, such as lower cardiovascular event rates. Second 
Fourth, American Heart Association guidelines did not recommend the routine use of 
CYP2C19 testing in acute coronary syndrome. However, in its recommendation, the 
Subcommittee did acknowledge specific clinical contexts in which CYP2C19 genotyping 
might be considered, such as patients who have had a cardiovascular event while on 
clopidogrel or patients who are at high risk for poor outcomes (Table 1).
DISCUSSION
In its first two years, the VHA Clinical Pharmacogenetics Subcommittee of the Molecular 
Diagnostics Working Group has made policy recommendations regarding the routine use of 
30 pharmacogenetic tests in clinical care at VHA facilities. Despite high grades of 
PharmGKB evidence supporting these drug-gene associations and strong CPIC 
recommendations for drug dosing if associated genotype is known, the Subcommittee voted 
to strongly recommend or recommend only about half of the tests it reviewed. Considered 
with other factors such as feasibility, cost, and patient and provider acceptance, these 
recommendations will inform national VHA policy for pharmacogenetic testing.
The Subcommittee’s recommendations do not contradict the work of PharmGKB or CPIC 
but, rather, highlight the need for demonstrated improvements in patient outcomes before 
large healthcare systems might broadly implement pharmacogenetic testing outside of a 
research context. PharmGKB evaluates the clinical validity of drug-gene pairs, that is, the 
evidence supporting the association of a given gene or variant with a drug phenotype. CPIC 
issues guidelines for drug dosing when genotype is already known but does not make 
recommendations on whether testing should be initiated in the first place. The gap between 
the work of PharmGKB and CPIC and the Subcommittee’s recommendations is one of 
clinical utility, a reason often cited by payers for not covering new laboratory tests.7,28,29 
There is no universally accepted definition of clinical utility.30,31 However, for the 
pharmacogenetics context, the Subcommittee’s consensus definition (“likelihood that 
pharmacogenetic information will lead to a change in clinical management that improves 
health outcomes”) refers to the impact of testing on at least two related categories of 
outcomes. First, clinical utility encompasses actionability, evidence that the 
pharmacogenetic result changes healthcare providers’ clinical management in terms of drug 
choice and dose.32,33 Management change would seem to be the minimum necessary 
demonstration of a pharmacogenetic test’s clinical utility, consistent with the conventional 
clinical wisdom of not ordering a test unless its results will change medical decision-
making. Second, a pharmacogenetic test ideally has prospectively collected evidence that the 
management change it prompts results in improved clinical outcomes, such as lower rates of 
adverse drug effects (drug safety) or prevention or better treatment of the associated 
condition (drug efficacy). The Subcommittee’s deliberations underscored the dearth of such 
evidence for many drug-gene pairs, despite their high clinical validity.
Other healthcare delivery systems have grappled with the question of which 
pharmacogenetic tests to implement in their clinical activities, using varying criteria to guide 
decision-making. The National Institutes of Health Clinical Center chose HLA genotyping 
to launch its Pharmacogenetics Testing Implementation Committee because of local 
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capabilities.34 St. Jude Children’s Research Hospital launched its pharmacist-managed 
Clinical Pharmacogenetics Service with thiopurine methyltransferase (TPMT) and uridine 
glucuronosyltransferase 1A1 (UGT1A1) testing, guided by the importance of azathioprine, 
mercaptopurine, thioguanine, and irinotecan in pediatric oncology but also by Phillips’ 
recommendations that a clinically important pharmacogenetic test applies to a commonly 
used medication with a high incidence of severe toxicity and a relatively common at-risk 
genotype, among other criteria.35,36 Institutions where patient genotypes are already 
preemptively available through clinical care, biobanks, or other research projects often use 
CPIC recommendations to choose which pharmacogenetic results to implement clinically.37 
At the national level, the Centers for Disease Control and Prevention (CDC) Office of Public 
Health Genomics performs horizon scanning of FDA policies, Centers for Medicare & 
Medicaid Services coverage decisions, clinical practice guidelines, and systematic reviews to 
rank the evidence supporting the clinical use of genomic tests, including certain 
pharmacogenetic tests.38 All four of the Subcommittee’s strongly recommended drug-gene 
pairs are categorized as “Tier 1” by the CDC, indicating readiness for clinical 
implementation.38,39 No one approach to evidence review and policymaking will apply to all 
healthcare contexts.
It is likely that some external pharmacogenetics experts and stakeholders will disagree with 
the Subcommittee’s recommendations for specific drug-gene pairs. We do not intend for 
these recommendations to supplant the work of organizations such as PharmGKB and CPIC. 
Instead, we present them to illustrate how one large integrated health system is building on 
their work and using context-specific considerations to inform policymaking around 
pharmacogenetic testing. It is important to note that the Subcommittee’s recommendations 
are meant to serve as guidance, not dogma, for VHA policymakers. The Subcommittee 
initially considered designating some drug-gene pairs as required, modeled after FDA black 
box warnings, but members expressed unease using this term, reluctant to apply a rigid 
designation suggesting that not testing would be inappropriate care, particularly in the 
absence of systems to facilitate testing. Within the Subcommittee, members held differing 
opinions on whether evidence from large randomized controlled trials (RCTs) is necessary 
to determine clinical utility, recognizing the impossibility of conducting RCTs to study all 
potential subgroups of patients who might benefit from pharmacogenetic testing. The 
Subcommittee also intends to update its recommendations and annotations as new scientific 
evidence accrues. For example, results of an RCT published after April 2017 prompted the 
Subcommittee to add an annotation that pharmacogenetic testing might be recommended for 
patients initiating perioperative warfarin for elective orthopedic surgery.40
This work has limitations to note. The Subcommittee used targeted evidence review of 
resources including PharmGKB and CPIC and did not perform independent systematic 
literature reviews to guide its deliberations. Second, its recommendations apply only to 
reactive pharmacogenetic testing, or test ordering at the clinical moment of medical 
decision-making around pharmacotherapy. Many have argued that preemptive testing, 
whereby patients undergo pharmacogenetic (or even broader genomic) testing early in the 
life course to inform medical care, will prove a more efficient and even cost-effective model;
8,9
 indeed, CPIC guidelines rest on this premise17 and thus cannot fully inform the 
Subcommittee’s work. Third, the Subcommittee’s recommendations apply only to testing 
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for individual drug-gene pairs instead of pharmacogenetic panel testing, which may provide 
efficiencies of scale as the costs of genotyping decrease. Fourth, the Subcommittee’s specific 
recommendations cannot necessarily be generalized to healthcare settings outside VHA; 
still, this description of the process of VHA policy recommendation may be informative for 
other health systems. Fifth, the Subcommittee did not explicitly consider the costs of 
pharmacogenetic testing in its deliberation; any VHA policies stemming from the 
Subcommittee’s recommendations will need to do so.
As the VHA Office of Specialty Care Services considers incorporating the Subcommittee’s 
recommendations into VHA policy, implementation and dissemination strategies will be 
needed to promote appropriate testing in the healthcare system. One strategy to decrease 
inappropriate pharmacogenetic testing is already in place in the VA San Diego Healthcare 
System (VASDHS), where a healthcare provider must request a pharmacogenomics e-
consult through the EHR to obtain approval from a clinical pharmacogenetic expert before 
ordering certain tests. This pharmacist reviews the literature and identifies the strength of the 
evidence linking the test to the medication to be prescribed, evaluates the benefit of the test 
to the medication, and approves or disapproves the test. Once approved, the VASDHS 
clinical laboratory processes the test for send-out. The pharmacist expert writes a consult 
note to inform the providers about the proper utilization, risks, benefits, and costs of using 
the test results for the medication. Strategies to increase appropriate pharmacogenetic testing 
also include academic detailing and pharmacist review of prescriptions for medications 
requiring pharmacogenetic testing. Additionally, appropriate testing can be promoted 
through clinical decision support integrated into the EHR, including web-based point-of-care 
resources to educate clinicians and alerts prompting prescribers to consider testing at the 
clinical moment a medication is prescribed.34 The Subcommittee’s recommendations and 
annotations will be continually updated as new evidence accrues. To accelerate such 
evidence generation, the VHA Office of Research & Development is currently funding 
ongoing RCTs of pharmacogenetic testing in the treatment of major depressive disorder 
(ClinicalTrials.gov Identifier: NCT03170362) and cardiovascular risk reduction 
(ClinicalTrials.gov Identifier: NCT02871934). The Subcommittee’s work highlights the 
need for additional rigorous outcomes research to promote the translation of 
pharmacogenetic discovery into patient care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
JLV is supported by Career Development Award IK2-CX001262 from the Clinical Sciences Research and 
Development (CSR&D) Service of the US Department of Veterans Affairs (VA). VMP is supported by the IGNITE 
project grant (U01-HG007762) from the National Institutes of Health and the Indiana University Health – Indiana 
University School of Medicine Strategic Research Initiative. The Pharmacogenomics Analysis Laboratory at the 
Central Arkansas Veterans Healthcare System is funded by the Cooperative Studies Program of the VA CSR&D 
Service. The contents do not necessarily represent the views of the US government or the VA.
Vassy et al. Page 10
Genet Med. Author manuscript; available in PMC 2019 August 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
REFERENCES
1. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the 
future is here. Genet Med. 2013;15(4):258–267. [PubMed: 23306799] 
2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. 
[PubMed: 26469045] 
3. Drew L Pharmacogenetics: The right drug for you. Nature. 2016;537(7619):S60–62. [PubMed: 
27602742] 
4. United States Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug 
Labels. 2017; https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. Accessed March 24, 
2018.
5. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with 
preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–431. [PubMed: 
24253661] 
6. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011;13(12):987–
995. [PubMed: 22095251] 
7. Patel HN, Ursan ID, Zueger PM, Cavallari LH, Pickard AS. Stakeholder views on 
pharmacogenomic testing. Pharmacotherapy. 2014;34(2):151–165. [PubMed: 24167008] 
8. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics 
implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 
2015;55:89–106. [PubMed: 25292429] 
9. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of 
the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo 
Clin Proc. 2014;89(1):25–33. [PubMed: 24388019] 
10. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the 
eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health 
record systems. Clin Pharmacol Ther. 2014;96(4):482–489. [PubMed: 24960519] 
11. Luzum JA, Pakyz RE, Elsey AR, et al. The Pharmacogenomics Research Network Translational 
Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across 
Diverse Healthcare Systems. Clin Pharmacol Ther. 2017;102(3):502–510. [PubMed: 28090649] 
12. O’Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics 
implementation program during outpatient care--initial results of the University of Chicago “1,200 
Patients Project”. Am J Med Genet C Semin Med Genet. 2014;166c(1):68–75.
13. van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing Pharmacogenomics in 
Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. 
Clin Pharmacol Ther. 2017;101(3):341–358. [PubMed: 28027596] 
14. Empey PE, Stevenson JM, Tuteja S, et al. Multi-site investigation of strategies for the 
implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther. 2017. 
[Epub ahead of print]
15. Department of Veterans Affairs. VHA Handbook 1106.01: Pathology and Laboratory Medicine 
Service Procedures. 2016; https://www.va.gov/vhapublications/ViewPublication.asp?
pub_ID=3169. Accessed March 24, 2018.
16. Wang B, Canestaro WJ, Choudhry NK. Clinical evidence supporting pharmacogenomic biomarker 
testing provided in US Food and Drug Administration drug labels. JAMA Intern Med. 
2014;174(12):1938–1944. [PubMed: 25317785] 
17. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical 
practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline 
development process. Current Drug Metabolism. 2014;15(2):209–217. [PubMed: 24479687] 
18. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for 
personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. [PubMed: 22992668] 
19. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the 
Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–467. [PubMed: 
21270786] 
Vassy et al. Page 11
Genet Med. Author manuscript; available in PMC 2019 August 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
20. Haddow J, Palomaki G. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests 
In: Khoury M, Little J, Burke W, eds. Human Genome Epidemiology. Oxford: Oxford University 
Press; 2004:217–233.
21. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The 
Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 
(CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2017.
22. PharmaADME. 2017; http://www.pharmaadme.org/. Accessed March 24, 2018.
23. International SAE Consortium. 2017; https://www.saeconsortium.org/. Accessed March 24, 2018.
24. Pharmacogenetics of Membrane Transporters Database. 2015; http://pharmacogenetics.ucsf.edu/. 
Accessed March 24, 2018.
25. Martin MA, Klein TE, Dong BJ, et al. Clinical Pharmacogenetics Implementation Consortium 
Guidelines for HLA-B Genotype and Abacavir Dosing. Clin Pharmacol Ther. 2012;91(4):734–
738. [PubMed: 22378157] 
26. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation 
Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin 
Pharmacol Ther. 2014;95(4):376–382. [PubMed: 24458010] 
27. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium 
guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 
2013;94(3):317–323. [PubMed: 23698643] 
28. Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive 
pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 
2017. [Epub ahead of print]
29. Hess GP, Fonseca E, Scott R, Fagerness J. Pharmacogenomic and pharmacogenetic-guided therapy 
as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. 
Genetics Research. 2015;97:e13. [PubMed: 26030725] 
30. ACMG Board of Directors. Clinical utility of genetic and genomic services: a position statement of 
the American College of Medical Genetics and Genomics. Genet Med. 2015;17:505. [PubMed: 
25764213] 
31. Drozda K, Pacanowski MA. Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic 
Testing. Pharmacotherapy. 2017;37(9):1000–1004. [PubMed: 28605049] 
32. Snyder SR, Mitropoulou C, Patrinos GP, Williams MS. Economic Evaluation of 
Pharmacogenomics: A Value-Based Approach to Pragmatic Decision Making in the Face of 
Complexity. Public Health Genomics. 2014;17(5–6):256–264. [PubMed: 25278172] 
33. O’Donnell PH, Wadhwa N, Danahey K, et al. Pharmacogenomics-Based Point-of-Care Clinical 
Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 11;102(5):
859–869. [PubMed: 28398598] 
34. Goldspiel BR, Flegel WA, DiPatrizio G, et al. Integrating pharmacogenetic information and clinical 
decision support into the electronic health record. J Am Med Inform Assoc. 2014;21(3):522–528. 
[PubMed: 24302286] 
35. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-
managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011;68(2):143–150. 
[PubMed: 21200062] 
36. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in 
reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–2279. [PubMed: 
11710893] 
37. Sperber NR, Carpenter JS, Cavallari LH, et al. Challenges and strategies for implementing 
genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE 
(IGNITE) network. BMC Med Genomics. 2017;10(1):35. [PubMed: 28532511] 
38. Dotson WD, Douglas MP, Kolor K, et al. Prioritizing genomic applications for action by level of 
evidence: a horizon-scanning method. Clin Pharmacol Ther. 2014;95(4):394–402. [PubMed: 
24398597] 
39. Centers for Disease Control and Prevention Office of Public Health Genomics. Public Health 
Genomics Knowledge Base (v2.1): Tier Table Database. 2017; https://phgkb.cdc.gov/PHGKB/
topicFinder.action?Mysubmit=init&query=all. Accessed March 24, 2018.
Vassy et al. Page 12
Genet Med. Author manuscript; available in PMC 2019 August 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
40. Gage BF, Bass AR, Lin H, et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events 
and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT 
Randomized Clinical Trial. JAMA. 2017;318(12):1115–1124. [PubMed: 28973620] 
Vassy et al. Page 13
Genet Med. Author manuscript; available in PMC 2019 August 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
Vassy et al. Page 14
TABLE 1:
VHA Clinical Pharmacogenetics Subcommittee recommendations for routine use of pharmacogenetic testing
Drug-gene pair(s) Rationale for recommendation
Annotations on special 
circumstances
Strongly recommended
Abacavir and HLA-B
RCT data showing avoidance of hypersensitivity reaction with test-
guided therapy. FDA label recommendation for testing prior to 
abacavir initiation.
--
Carbamazepine and HLA-B Severity of SJS/TEN. Availability of alternate anticonvulsant therapy. --
Ivacaftor and CFTR Drug indicated only for cystic fibrosis patients with specific CFTR 
variants. --
Rasburicase and G6PD Severity of hemolytic anemia. Availability of alternate urate-lowering therapy. --
Recommended
Allopurinol and HLA-B Severity of cutaneous adverse reactions. Drug already in widespread 
routine use across VHA. --
Azathioprine and TPMT Either genotyping or phenotyping can guide drug dosing. --
Boceprevir and IFNL3 Genotyping can guide choice of hepatitis C therapy. Recommended for treatment-
naïve patients only
Codeine and CYP2D6 Alternate drugs available for poor and ultrarapid codeine 
metabolizers. Drug not commonly used in VHA. --
Mercaptopurine and TPMT* Either genotyping or phenotyping can guide drug dosing. --
Peginterferon alfa-2a and IFNL3 Genotyping can guide choice of hepatitis C therapy. Recommended for treatment-
naïve patients only
Peginterferon alfa-2b and IFNL3 Genotyping can guide choice of hepatitis C therapy. Recommended for treatment-
naïve patients only
Phenytoin and HLA-B Severity of hypersensitivity reaction. Drug already in widespread 
routine use across VHA. --
Ribavirin and IFNL3 Genotyping can guide choice of hepatitis C therapy. Recommended for treatment-
naïve patients only
Tamoxifen and CYP2D6**
Genotyping can guide alternate therapy, but CYP2D6 genotyping is 
technically difficult and improved therapeutic outcomes have not 
been established.
--
Telaprevir and IFNL3 Genotyping can guide choice of hepatitis C therapy. Recommended for treatment-
naïve patients only
Thioguanine and TPMT Either genotyping or phenotyping can guide drug dosing. --
Not routinely recommended
Amitriptyline and CYP2C19, 
CYP2D6
Drug already in widespread routine use across VHA. Improved 
patient outcomes with testing not established. --
Capecitabine and DPYD Severe toxicity attributable to dihydropyrimidine dehydrogenase deficiency is rare.
May be considered for patients 
with severe toxicity (neutropenia, 
nausea, vomiting, severe 
diarrhea, stomatitis, mucositis, 
hand-foot syndrome, neuropathy)
Clomipramine and CYP2C19, 
CYP2D6 Improved patient outcomes with testing not established. --
Clopidogrel and CYP2C19
Genotyping or platelet aggregometry can guide therapy. Improved 
patient outcomes with testing not established. Absence of AHA 
guideline supporting testing.
May be considered for patients 
with recurrent coronary events 
despite ongoing clopidogrel 
therapy and patients at high risk 
for poor outcomes
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Drug-gene pair(s) Rationale for recommendation
Annotations on special 
circumstances
Desipramine and CYP2D6 Improved patient outcomes with testing not established. --
Doxepine and CYP2C19, 
CYP2D6 Improved patient outcomes with testing not established. --
Fluorouracil and DPYD Severe toxicity attributable to dihydropyrimidine dehydrogenase deficiency is rare.
May be considered for patients 
with severe toxicity (neutropenia, 
nausea, vomiting, severe 
diarrhea, stomatitis, mucositis, 
hand-foot syndrome, neuropathy)
Imipramine and CYP2C19, 
CYP2D6 Improved patient outcomes with testing not established. --
Nortriptyline and CYP2D6 Drug already in widespread routine use across VHA. Improved patient outcomes with testing not established. --
Phenytoin and CYP2C9
Either genotyping or phenytoin levels can guide drug dosing. Drug 
already in widespread routine use across VHA. Improved patient 
outcomes with testing not established.
May be considered to achieve 
steady-state concentrations 
quickly for life-threatening 
circumstances such as refractory 
status epilepticus
Simvastatin and SLCO1B1 Drug already in widespread routine use across VHA. Improved patient outcomes with testing not established. --
Tegafur and DPYD Severe toxicity attributable to dihydropyrimidine dehydrogenase deficiency is rare.
May be considered for patients 
with severe toxicity (neutropenia, 
nausea, vomiting, severe 
diarrhea, stomatitis, mucositis, 
hand-foot syndrome, neuropathy)
Trimipramine and CYP2C19, 
CYP2D6 Improved patient outcomes with testing not established. --
Warfarin and CYP2C9, VKORC1 Improved patient outcomes with testing not established. Published dosing guidelines are variable.
May be considered for frail 
elderly patients whose risk-
benefit ratio favors 
anticoagulation or for those 
whose INR fluctuations create 
dosing strategy dilemmas
Unless noted otherwise, all drug-gene pairs have PharmGKB Clinical Annotation Level of Evidence 1A, indicating a variant-drug combination in a 
Clinical Pharmacogenetics Implementation Consortium (CPIC) or medical society-endorsed pharmacogenetic guideline or implemented at a 
Pharmacogenomics Research Network site or in another major health system. All drug-gene pairs had CPIC recommendations of Level A strength, 
indicating drug-gene pairs for which available pharmacogenetic results should be used to change the prescribing of the drug in question, based on 
moderate to high evidence and at least one moderate or strong recommendation.
Abbreviations: AHA: American Heart Association; INR: international normalized ratio; RCT: randomized controlled trial; SJS/TEN: Stevens-
Johnson syndrome/toxic epidermal necrolysis; VHA: Veterans Health Administration
*
PharmGKB Level 1B, indicating a variant-drug combination where the preponderance of evidence shows an association.
**At time of Subcommittee’s initial review, PharmGKB Level 2A, indicating a variant-drug combination with moderate evidence of association in 
known pharmacogenes, but subsequently upgraded to 1A.
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